Related Experiment Video
Updated: Jan 4, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Traf6 inhibitor boosts antitumor immunity by impeding regulatory T cell migration in Hepa1-6 tumor model
Xiao Wu1, Rong Xue2, Hao Peng1
1Translational Medicine Research Center of Affiliated Jiangning Hospital, Liver Transplantation Center of First Affiliated Hospital, and Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract:
Tumors escape immune attacks via various mechanisms, among which activation of regulatory pathways in effector immune cells and recruitment of immunosuppressive cells are usually employed. Traf6 is a member of the family of tumor necrosis factor receptor-associated factors and involved in many signaling pathways. While it plays important roles in both tumor biology and immune system, the potential therapeutic role of Traf6 in tumor immunotherapy hasn't ever been assessed. Here, we confirmed the anti-tumor effect of Traf6 inhibitor in Hepa1-6 tumor model. Flow cytometry-based analysis revealed that T cell-mediated antitumor immunity was provoked and the infiltration of Treg cells was restrained when treated with Traf6 inhibitor. Via an in vivo migration assay, we found that Traf6 inhibitor decreased the population of intratumor Tregs by impeding the migration of Tregs towards tumor. Finally, we demonstrated that combination of Traf6 inhibitor and PD-1 blockade could receive a better antitumor efficiency. These results implicated that Traf6 inhibitor could serve as a supplement for immune checkpoint therapy.
Insights
A novel Traf6 inhibitor shows anti-tumor effects by enhancing T cell immunity and reducing immunosuppressive cells. Combining Traf6 inhibition with PD-1 blockade improves therapeutic outcomes in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumors evade immune surveillance through mechanisms like regulatory pathway activation and immunosuppressive cell recruitment.
- Tumor necrosis factor receptor-associated factor 6 (Traf6) is implicated in immune signaling and tumor biology, but its therapeutic potential in cancer immunotherapy remains unexplored.
Purpose of the Study:
- To investigate the anti-tumor efficacy of a Traf6 inhibitor in a preclinical cancer model.
- To elucidate the impact of Traf6 inhibition on anti-tumor immunity, including T cell responses and regulatory T cell (Treg) infiltration.
- To evaluate the synergistic potential of combining a Traf6 inhibitor with PD-1 blockade for enhanced anti-tumor activity.
Main Methods:
- Utilized a Hepa1-6 tumor model to assess the anti-tumor effect of a Traf6 inhibitor.
- Employed flow cytometry to analyze T cell-mediated immunity and Treg cell infiltration.
- Conducted an in vivo migration assay to determine the effect of Traf6 inhibitor on Treg cell migration towards tumors.
Main Results:
- The Traf6 inhibitor demonstrated significant anti-tumor effects in the Hepa1-6 model.
- Treatment with the Traf6 inhibitor enhanced T cell-mediated anti-tumor immunity and reduced Treg cell infiltration.
- The Traf6 inhibitor was found to impede Treg cell migration into tumors.
- Combination therapy with the Traf6 inhibitor and PD-1 blockade yielded superior anti-tumor efficacy compared to monotherapy.
Conclusions:
- Traf6 inhibition exhibits anti-tumor properties by modulating the tumor immune microenvironment.
- Traf6 inhibition can enhance anti-tumor immunity and suppress the migration of immunosuppressive Treg cells.
- Traf6 inhibitors represent a promising therapeutic strategy, potentially augmenting the effectiveness of immune checkpoint therapies like PD-1 blockade.
